{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:51:52Z","timestamp":1791478312214,"version":"4.3.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s10557-026-07855-w","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T10:51:03Z","timestamp":1771411863000},"page":"1629-1635","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The 2025 ESC\/EAS Dyslipidaemia Focused Update: Clinical Interpretation and Practical Implications"],"prefix":"10.1007","volume":"40","author":[{"given":"Luca","family":"Bonanni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada","family":"Cutolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Ferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"7855_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf190","author":"F Mach","year":"2025","unstructured":"Mach F, Koskinas KC, van Roeters JE, et al. 2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2025. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf190.","journal-title":"Eur Heart J"},{"issue":"11","key":"7855_CR2","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1093\/cvr\/cvaa154","volume":"116","author":"S Windecker","year":"2020","unstructured":"Windecker S. ESC committee for practice guidelines: providing knowledge to everyday clinical practice. Cardiovascular Res. 2020;116(11):e146\u20138. https:\/\/doi.org\/10.1093\/cvr\/cvaa154.","journal-title":"Cardiovascular Res"},{"issue":"25","key":"7855_CR3","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","volume":"42","author":"Group Sw, collaboration ESCCr","year":"2021","unstructured":"Group Sw, collaboration ESCCr. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42(25):2439\u201354. https:\/\/doi.org\/10.1093\/eurheartj\/ehab309.","journal-title":"Eur Heart J"},{"issue":"15","key":"7855_CR4","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","volume":"388","author":"SE Nissen","year":"2023","unstructured":"Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in Statin-Intolerant patients. N Engl J Med. 2023;388(15):1353\u201364. https:\/\/doi.org\/10.1056\/NEJMoa2215024.","journal-title":"N Engl J Med"},{"issue":"8","key":"7855_CR5","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa2004215","volume":"383","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for homozygous Familial hypercholesterolemia. New Engl J Med. 2020;383(8):711\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2004215.","journal-title":"New Engl J Med"},{"issue":"8","key":"7855_CR6","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2304146","volume":"389","author":"SK Grinspoon","year":"2023","unstructured":"Grinspoon SK, Fitch KV, Zanni MV, et al. Pitavastatin to prevent cardiovascular disease in HIV infection. N Engl J Med. 2023;389(8):687\u201399. https:\/\/doi.org\/10.1056\/NEJMoa2304146.","journal-title":"N Engl J Med"},{"issue":"22","key":"7855_CR7","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1001\/jama.2020.22258","volume":"324","author":"SJ Nicholls","year":"2020","unstructured":"Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-Dose Omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA. 2020;324(22):2268\u201380. https:\/\/doi.org\/10.1001\/jama.2020.22258.","journal-title":"JAMA"},{"issue":"6","key":"7855_CR8","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1161\/CIRCULATIONAHA.120.052209","volume":"143","author":"AA Kalstad","year":"2021","unstructured":"Kalstad AA, Myhre PL, Laake K, et al. Effects of n-3 fatty acid supplements in elderly patients after myocardial infarction: A Randomized, controlled trial. Circulation. 2021;143(6):528\u201339. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.052209.","journal-title":"Circulation"},{"issue":"6","key":"7855_CR9","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa1715944","volume":"381","author":"JL Witztum","year":"2019","unstructured":"Witztum JL, Gaudet D, Freedman SD, et al. Volanesorsen and triglyceride levels in Familial chylomicronemia syndrome. N Engl J Med. 2019;381(6):531\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1715944.","journal-title":"N Engl J Med"},{"issue":"8","key":"7855_CR10","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1093\/eurheartj\/ehab718","volume":"43","author":"KK Ray","year":"2022","unstructured":"Ray KK, Reeskamp LF, Laufs U, et al. Combination lipid-lowering therapy as first-line strategy in very high-risk patients. Eur Heart J. 2022;43(8):830\u20133. https:\/\/doi.org\/10.1093\/eurheartj\/ehab718.","journal-title":"Eur Heart J"},{"issue":"10","key":"7855_CR11","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1016\/j.numecd.2023.07.019","volume":"33","author":"G Chiesa","year":"2023","unstructured":"Chiesa G, Zenti MG, Baragetti A, et al. Consensus document on Lipoprotein(a) from the Italian society for the study of atherosclerosis (SISA). Nutrition, metabolism, and cardiovascular diseases. NMCD. 2023;33(10):1866\u201377. https:\/\/doi.org\/10.1016\/j.numecd.2023.07.019.","journal-title":"NMCD"},{"issue":"15","key":"7855_CR12","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1093\/eurjpc\/zwad187","volume":"30","author":"SHJ Hageman","year":"2023","unstructured":"Hageman SHJ, Petitjaen C, Pennells L, et al. Improving 10-year cardiovascular risk prediction in apparently healthy people: flexible addition of risk modifiers on top of SCORE2. Eur J Prev Cardiol. 2023;30(15):1705\u201314. https:\/\/doi.org\/10.1093\/eurjpc\/zwad187.","journal-title":"Eur J Prev Cardiol"},{"issue":"18","key":"7855_CR13","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1615664.","journal-title":"N Engl J Med"},{"issue":"22","key":"7855_CR14","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107. https:\/\/doi.org\/10.1056\/NEJMoa1801174.","journal-title":"N Engl J Med"},{"issue":"11","key":"7855_CR15","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","volume":"28","author":"KK Ray","year":"2021","unstructured":"Ray KK, Molemans B, Schoonen WM, et al. EU-Wide Cross-Sectional observational study of Lipid-Modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol. 2021;28(11):1279\u201389. https:\/\/doi.org\/10.1093\/eurjpc\/zwaa047.","journal-title":"Eur J Prev Cardiol"},{"key":"7855_CR16","doi-asserted-by":"publisher","first-page":"100624","DOI":"10.1016\/j.lanepe.2023.100624","volume":"29","author":"KK Ray","year":"2023","unstructured":"Ray KK, Haq I, Bilitou A, et al. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. Lancet Reg Health Eur. 2023;29:100624. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100624.","journal-title":"Lancet Reg Health Eur"},{"issue":"6","key":"7855_CR17","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1056\/NEJMc2033612","volume":"384","author":"F Luo","year":"2021","unstructured":"Luo F, Das A, Fang Z. Evinacumab for homozygous Familial hypercholesterolemia. N Engl J Med. 2021;384(6):e17. https:\/\/doi.org\/10.1056\/NEJMc2033612.","journal-title":"N Engl J Med"},{"key":"7855_CR18","doi-asserted-by":"publisher","unstructured":"Ferri N, Colombo E, Corsini A. Bempedoic Acid, the First-in-Class oral ATP citrate lyase inhibitor with hypocholesterolemic activity: clinical Pharmacology and Drug-Drug interactions. Pharmaceutics. 2024;16(11). https:\/\/doi.org\/10.3390\/pharmaceutics16111371.","DOI":"10.3390\/pharmaceutics16111371"},{"issue":"2","key":"7855_CR19","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jacc.2024.04.048","volume":"84","author":"AM Lincoff","year":"2024","unstructured":"Lincoff AM, Ray KK, Sasiela WJ, et al. Comparative cardiovascular benefits of bempedoic acid and Statin drugs. J Am Coll Cardiol. 2024;84(2):152\u201362. https:\/\/doi.org\/10.1016\/j.jacc.2024.04.048.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"7855_CR20","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.jacl.2020.08.009","volume":"14","author":"HE Bays","year":"2020","unstructured":"Bays HE, Banach M, Catapano AL, et al. Bempedoic acid safety analysis: pooled data from four phase 3 clinical trials. J Clin Lipidol. 2020;14(5):649\u201359. https:\/\/doi.org\/10.1016\/j.jacl.2020.08.009. e6.","journal-title":"J Clin Lipidol"},{"issue":"3","key":"7855_CR21","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1093\/eurheartj\/ehaa1008","volume":"42","author":"KK Ray","year":"2021","unstructured":"Ray KK. Changing the paradigm for post-MI cholesterol Lowering from intensive Statin monotherapy towards intensive lipid-lowering regimens and individualized care. Eur Heart J. 2021;42(3):253\u20136. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa1008.","journal-title":"Eur Heart J"},{"key":"7855_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-025-07781-3","author":"L Bonanni","year":"2025","unstructured":"Bonanni L, Ferri N. Bempedoic acid and the uric acid paradox: reflections on the recent Meta-analysis. Cardiovasc Drugs Ther. 2025. https:\/\/doi.org\/10.1007\/s10557-025-07781-3.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"16","key":"7855_CR23","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1912387.","journal-title":"N Engl J Med"},{"key":"7855_CR24","doi-asserted-by":"publisher","first-page":"117354","DOI":"10.1016\/j.atherosclerosis.2023.117354","volume":"386","author":"U Landmesser","year":"2023","unstructured":"Landmesser U, Koenig W, Leiter LA, et al. Inclisiran in patients with prior myocardial infarction: A post hoc pooled analysis of the ORION-10 and ORION-11 phase 3 randomised trials. Atherosclerosis. 2023;386:117354. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2023.117354.","journal-title":"Atherosclerosis"},{"key":"7855_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-025-07749-3","author":"F Briani","year":"2025","unstructured":"Briani F, Sani E, Venturi G, et al. Real-World efficacy of inclisiran in Veneto region (Italy): the INCLIVEN multicenter registry. Cardiovasc Drugs Ther. 2025. https:\/\/doi.org\/10.1007\/s10557-025-07749-3.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"3","key":"7855_CR26","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41591-023-02222-w","volume":"29","author":"RS Rosenson","year":"2023","unstructured":"Rosenson RS, Gaudet D, Ballantyne CM, et al. Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial. Nat Med. 2023;29(3):729\u201337. https:\/\/doi.org\/10.1038\/s41591-023-02222-w.","journal-title":"Nat Med"},{"key":"7855_CR27","doi-asserted-by":"publisher","unstructured":"Hundley WG, D\u2019Agostino R Jr., Crotts T, et al. Statins and left ventricular ejection fraction following doxorubicin treatment. NEJM Evid. 2022;1(9). https:\/\/doi.org\/10.1056\/evidoa2200097.","DOI":"10.1056\/evidoa2200097"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07855-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-026-07855-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07855-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T09:08:00Z","timestamp":1784624880000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-026-07855-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["7855"],"URL":"https:\/\/doi.org\/10.1007\/s10557-026-07855-w","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}